{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RPV+LA&page=2", "query": { "intervention": "RPV LA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RPV+LA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-02T03:03:16.479Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05917509", "title": "A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG/3TC", "type": "DRUG" }, { "name": "Cabotegravir (CAB) LA", "type": "DRUG" }, { "name": "Rilpivirine (RPV) LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2023-07-06", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05917509" }, { "nct_id": "NCT02120352", "title": "A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "CAB Oral Tablets", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "ABC/3TC Oral tablets", "type": "DRUG" }, { "name": "RPV Oral Tablets", "type": "DRUG" }, { "name": "HAART", "type": "OTHER" }, { "name": "RPV", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2014-04-28", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2024-06-12", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120352" }, { "nct_id": "NCT03639311", "title": "Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB LA", "type": "DRUG" }, { "name": "RPV LA", "type": "DRUG" }, { "name": "RPV", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2018-09-24", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639311" }, { "nct_id": "NCT07637942", "title": "Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV -1 Infection" ], "interventions": [ { "name": "Every 4-week long-acting injectable cabotegravir and rilpivirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2026-10-15", "completion_date": "2028-03-22", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 10, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07637942" }, { "nct_id": "NCT05112939", "title": "A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "RPV LA", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 126, "start_date": "2021-11-16", "completion_date": "2024-05-23", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 2, "location_summary": "Lenexa, Kansas • Salt Lake City, Utah", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05112939" }, { "nct_id": "NCT07650916", "title": "A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CAB ULA", "type": "DRUG" }, { "name": "RPV ULA", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "RPV LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 564, "start_date": "2026-06-25", "completion_date": "2029-09-04", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07650916" }, { "nct_id": "NCT06411223", "title": "Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hiv" ], "interventions": [ { "name": "Collaborative drug therapy management model", "type": "BEHAVIORAL" }, { "name": "Cabotegravir/Rilpivirine", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-08-01", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06411223" }, { "nct_id": "NCT05660980", "title": "Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Once daily CAB tablet + RPV tablet", "type": "DRUG" }, { "name": "Long acting CAB injectable + long acting RPV injectable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 90, "start_date": "2024-01-24", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Memphis, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660980" }, { "nct_id": "NCT02938520", "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "ABC/DTG/3TC STR - Tablet", "type": "DRUG" }, { "name": "DTG Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2016-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02938520" }, { "nct_id": "NCT04542070", "title": "A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Cabotegravir Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Rilpivirine Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "BIKTARVY Tablets (BIK)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2020-11-09", "completion_date": "2023-04-17", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-02T03:03:16.479Z", "location_count": 41, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04542070" } ] }